Perspectives for the management of febrile neutropenic patients with cancer in the 21st century

Cancer - Tập 103 Số 6 - Trang 1103-1113 - 2005
Nikolaos V. Sipsas1, Gerald P. Bodey, Dimitrios P. Kontoyiannis
1Infectious Diseases Unit, Pathophysiology Department, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Tóm tắt

AbstractOver the past several decades, there has been substantial progress in the management of patients with febrile neutropenia. However, the ever‐changing patterns of infection, ecology, and antibiotic‐resistance trends do not allow the development of treatment guidelines that could be applied universally. Hence, the institution's predominant pathogens and resistance patterns should guide the empirical choice of antimicrobials. Prompt initiation of antimicrobial therapy remains the gold standard. Monotherapy with the newer broad‐spectrum antimicrobials has tended to replace the classic combination therapy. Empirical administration of glycopeptides, such as vancomycin, without documentation of a gram‐positive infection is not favored. The development of risk‐stratification models has allowed for identification of low‐risk patients with additional treatment options, such as early discharge and exclusively outpatient treatment with oral antimicrobials. The initiation of empirical antifungal therapy in persistently febrile neutropenic patients has become common practice, especially recently, since the introduction of new, effective, less toxic antifungal drugs. It is hoped that the development of new nonculture‐based diagnostic methods will allow for the early detection of invasive fungal infections and, thus, the replacement of empirical antifungal therapy with pathogen‐specific, preemptive therapy. Cancer 2005. © 2005 American Cancer Society.

Từ khóa


Tài liệu tham khảo

10.1002/cncr.11380

10.1002/cncr.11882

Sickles EA, 1975, Clinical presentation of infection in granulocytopenic patients, Arch Intern Med., 135, 715, 10.1001/archinte.1975.00330050089015

Chrischilles E, 2002, Factors associated with early termination of CHOP, and its association with overall survival among patients with intermediate‐grade non‐Hodgkin's lymphoma (NHL), Proc Am Soc Clin Oncol., 21, 385a

10.1086/339215

10.1099/jmm.0.05076-0

10.7326/0003-4819-64-2-328

10.1007/978-3-642-60443-0_10

10.1086/374339

10.1086/378305

10.1001/archinte.160.4.501

10.1200/JCO.1998.16.3.1179

10.1086/345435

10.1086/322604

10.1097/00005792-198905000-00003

10.1093/clind/15.5.824

10.1002/cncr.11044

10.1093/jac/37.3.433

10.1086/340402

10.1093/jac/47.5.693

10.1093/clinids/14.6.1201

10.1093/clinids/20.2.296

10.1086/342904

10.1128/AAC.38.6.1363

Hachem RY, 2003, Molecular patterns of decreased vancomycin‐resistant Enterococcus faecium (VREF) susceptibility to linezolid associated with clinical use

10.1086/375818

10.1086/501787

10.1016/S0140-6736(03)14904-5

10.1093/clinids/14.4.875

10.1086/520192

10.1097/01.md.0000091182.93122.8e

10.1086/502104

10.1016/S0140-6736(02)08162-X

10.1007/s10096-002-0699-z

10.1016/S0732-8893(03)00013-0

10.1093/clinids/22.Supplement_2.S112

10.1093/jac/42.4.497

10.1002/cncr.11510

10.1016/S0924-8579(00)00241-7

10.1097/00000441-198401000-00004

10.1097/00005792-197705000-00005

10.7326/0003-4819-140-1-200401060-00007

Allen U, 1986, The value of skin biopsies in febrile, neutropenic, immunocompromised children, Am J Dis Child., 140, 459

10.1200/JCO.1999.17.3.796

10.1056/NEJMe048203

Talcott JA, 1988, The medical course of cancer patients with fever and neutropenia. Clinical identification of a low risk subgroup at presentation, Arch Intern Med., 148, 2561, 10.1001/archinte.1988.00380120031007

10.1086/514550

10.1200/JCO.1992.10.2.316

10.1200/JCO.2000.18.16.3038

10.1001/archinte.1962.03620240038007

10.1001/archinte.1985.00360090089015

10.1002/1097-0142(197208)30:2<573::AID-CNCR2820300238>3.0.CO;2-O

10.1056/NEJM197105132841904

10.1002/1097-0142(197804)41:4<1610::AID-CNCR2820410452>3.0.CO;2-B

10.1093/clinids/24.5.810

10.7326/0003-4819-137-2-200207160-00005

10.1056/NEJM198608283150905

Yamamura D, 1997, Open randomized study of cefepime versus piperacillin‐gentamicin for treatment of febrile neutropenic cancer patients, Antimicrob Agents Chemother., 41, 1704, 10.1128/AAC.41.8.1704

10.1128/AAC.40.5.1108

10.1002/(SICI)1097-0142(19980615)82:12<2449::AID-CNCR20>3.0.CO;2-O

10.1086/322646

Rolston KV, 1992, A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients, Arch Intern Med., 152, 283, 10.1001/archinte.1992.00400140037010

10.1200/JCO.2000.18.21.3690

10.1002/cncr.11613

10.1128/AAC.44.12.3264-3271.2000

10.1002/1097-0142(197206)29:6<1697::AID-CNCR2820290638>3.0.CO;2-K

10.1136/bmj.326.7399.1111

10.1007/s005200100300

Centers for Disease Control and Prevention, 1995, Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC), MMWR Morb Mortal Wkly Rep., 44, 1

10.1093/infdis/163.5.951

10.1086/598622

10.1097/00000441-197408000-00003

10.1038/sj.bjc.6600993

10.1002/1097-0142(19930601)71:11<3640::AID-CNCR2820711128>3.0.CO;2-H

10.1056/NEJM199907293410501

10.1056/NEJM199907293410502

10.1093/jac/dkh303

Gardenmbas‐Pain M, 1991, Home treatment of febrile neutropenia: an empirical oral antibiotic regimen, Ann Oncol., 2, 485, 10.1093/oxfordjournals.annonc.a057996

10.1200/JCO.2000.18.21.3699

10.1016/0002-9343(79)90390-5

10.1056/NEJM200201243460402

10.1007/s100960050453

10.1177/0148607184008005501

10.1097/00005792-198407000-00001

10.1097/00005792-199009000-00003

10.1002/1097-0142(19870715)60:2<255::AID-CNCR2820600224>3.0.CO;2-L

10.1016/0002-9343(82)90594-0

10.1001/archinte.148.1.129

10.1093/jac/45.6.843

10.1086/376637

10.7326/0003-4819-120-10-199405150-00004

10.1007/BF01967060

10.1053/jhin.2002.1278

Goldstone AH, 1994, Early AmBisome in febrile neutropenia in patients with haematological disorders, Bone Marrow Transplant., 14, S15